Psychedelic Spotlight Interview with Pierre Bouchard
In this episode of the Psychedelic Spotlight podcast, we speak…
In this episode of the Psychedelic Spotlight podcast, we speak…
In this episode of the Psychedelic Spotlight podcast, we spend…
In this episode of the Psychedelic Spotlight podcast, we speak…
HAVN Life Sciences Inc. CEO, Tim Moore, updates the recent…
In this Psychedelic Spotlight exclusive, we speak with California Senator,…
In this episode of the Psychedelic Spotlight podcast, we feature…
In this episode of the Psychedelic Spotlight podcast, we catch…
In this episode of the Psychedelic Spotlight podcast, we feature…
Podcaster and author of “The 4-Hour Work Week” will gift the university’s Center for the Science of Psychedelics $800,000 over 3 years to fund fellowship overseen by Professor Pollan.
Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.